Literature DB >> 2351931

Enhanced antigen immunogenicity induced by bispecific antibodies.

D P Snider1, A Kaubisch, D M Segal.   

Abstract

The binding of protein antigens to APC with heterocrosslinked bispecific antibodies (HBAs) enhances their processing and presentation to Th cells in vitro. Here we have asked whether HBAs could also increase immune responses in vivo. We immunized mice with hen egg lysozyme (HEL) in the presence or absence of HBA, and followed antibody production after the primary challenge and after a secondary boost. We found that HBAs that bind antigen to MHC class I or II molecules, to Fc gamma R, but not to surface IgD, enhance the immunogenicity of HEL. HBAs that bound HEL to MHC class II molecules, for examples, decreased the amount of antigen required to elicit a primary anti-HEL antibody response in mice by 300-fold, and the amount required to prime for a secondary response by 10(3)- to 10(4)-fold. In fact, HBAs were as effective as IFA in generating antibody responses. Since adjuvants cannot be used in humans, HBAs could prove useful for immunizing people, especially in cases where, due to scarcity or toxicity, minute doses of antigen must be used.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2351931      PMCID: PMC2187948          DOI: 10.1084/jem.171.6.1957

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

Review 1.  T-cell recognition of lysozyme: the biochemical basis of presentation.

Authors:  P M Allen; B P Babbitt; E R Unanue
Journal:  Immunol Rev       Date:  1987-08       Impact factor: 12.988

2.  Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein.

Authors:  B Dietzschold; H H Wang; C E Rupprecht; E Celis; M Tollis; H Ertl; E Heber-Katz; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

3.  Targeted antigen presentation using crosslinked antibody heteroaggregates.

Authors:  D P Snider; D M Segal
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

4.  Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.

Authors:  M J Glennie; H M McBride; A T Worth; G T Stevenson
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

5.  Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens.

Authors:  V T Oi; P P Jones; J W Goding; L A Herzenberg; L A Herzenberg
Journal:  Curr Top Microbiol Immunol       Date:  1978       Impact factor: 4.291

Review 6.  Are B lymphocytes the principal antigen-presenting cells in vivo?

Authors:  J D Ashwell
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

7.  Delivery of synthetic peptides by anti-class II MHC monoclonal antibodies induces specific adjuvant-free IgG responses in vivo.

Authors:  G Carayanniotis; E Vizi; J M Parker; R S Hodges; B H Barber
Journal:  Mol Immunol       Date:  1988-09       Impact factor: 4.407

8.  Efficiency of antigen presentation after antigen targeting to surface IgD, IgM, MHC, Fc gamma RII, and B220 molecules on murine splenic B cells.

Authors:  D P Snider; D M Segal
Journal:  J Immunol       Date:  1989-07-01       Impact factor: 5.422

9.  The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice.

Authors:  E A Kurt-Jones; D Liano; K A HayGlass; B Benacerraf; M S Sy; A K Abbas
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

10.  Fine specificity of the H-2 linked immune response gene for the gallinaceous lysozymes.

Authors:  S W Hill; E E Sercarz
Journal:  Eur J Immunol       Date:  1975-05       Impact factor: 5.532

View more
  13 in total

1.  Anti-class II monoclonal antibody-targeted Vibrio cholerae TcpA pilin: modulation of serologic response, epitope specificity, and isotype.

Authors:  J Y Wu; R K Taylor; W F Wade
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

2.  Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization.

Authors:  H Wang; M N Griffiths; D R Burton; P Ghazal
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 3.  Improving vaccines by targeting antigens to dendritic cells.

Authors:  Ken Shortman; Mireille H Lahoud; Irina Caminschi
Journal:  Exp Mol Med       Date:  2009-02-28       Impact factor: 8.718

Review 4.  Controlling immune responses by targeting antigens to dendritic cell subsets and B cells.

Authors:  Craig P Chappell; Natalia V Giltiay; Christiane Dresch; Edward A Clark
Journal:  Int Immunol       Date:  2013-11-27       Impact factor: 4.823

5.  Intranasal antigen targeting to MHC class II molecules primes local IgA and serum IgG antibody responses in mice.

Authors:  D P Snider; B J Underdown; M R McDermott
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

6.  A novel synthetic bipartite carrier protein for developing glycotope-based vaccines.

Authors:  Hsiao-Ling Chiang; Chi-Yu Lin; Fan-Dan Jan; Yaoh-Shiang Lin; Chia-Tse Hsu; Jacqueline Whang-Peng; Leroy F Liu; Shin Nieh; Chun-Cheng Lin; Jaulang Hwang
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

7.  Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region.

Authors:  Yi Zheng; Yijuan Zhang; Yuandong Ma; Jun Wan; Chaofan Shi; Laiqiang Huang
Journal:  J Microbiol       Date:  2008-12-24       Impact factor: 3.422

8.  Antitumor immunopreventive effect in mice induced by DNA vaccine encoding a fusion protein of alpha-fetoprotein and CTLA4.

Authors:  Geng Tian; Ji-Lin Yi; Ping Xiong
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

9.  Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis.

Authors:  Deepak B Rawool; Constantine Bitsaktsis; Ying Li; Diane R Gosselin; Yili Lin; Nitin V Kurkure; Dennis W Metzger; Edmund J Gosselin
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

10.  Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine.

Authors:  Christian Adam; Josef Mysliwietz; Ralph Mocikat
Journal:  J Transl Med       Date:  2007-03-14       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.